跳到正文
原文
Medical Xpress·· 2026-10-08AI 评分45

实验性抗癌平台Ctx-ETAC在动物实验中阻断细胞通讯以抑制肿瘤生长

Experimental cancer treatment disrupts cell communication to suppress tumor growth in animal tests

AI 导读

研究团队开发出靶向EGFR的降解剂-抗体偶联物Ctx-ETAC,通过降解细胞内的COX-2抑制细胞外囊泡分泌,阻断癌细胞与肿瘤相关成纤维细胞之间的通讯。在细胞实验中该偶联物降低了CAF活化、癌细胞迁移与促肿瘤巨噬细胞极化,在动物肿瘤模型中显著抑制肿瘤生长并使肿瘤微环境向抗肿瘤状态重塑。

正文
Developing Novel Cancer Therapy That Disrupts Communication Between Cancer Cells and Cancer-associated fibroblasts
Ctx-ETAC suppresses EV secretion, disrupts cancer-CAF communication, and induces CAF and macrophage reprogramming, ultimately inhibiting tumor progression and metastasis through EV network collapse. Credit: Eun Hye Kim, et al. Journal of the American Chemical Society https://doi.org/10.1021/jacs.6c11538

A research team has developed an anticancer treatment platform that simultaneously targets cancer cells and the surrounding cells that support them while blocking communication between the two.

The paper is published in the Journal of the American Chemical Society. The researchers were led by Professor Yoosoo Yang of the Department of Integrative Biotechnology at Sungkyunkwan University (SKKU), in collaboration with a research team led by Dr. Man Kyu Shim of the Korea Institute of Science and Technology (KIST).

A support network around cancer cells

Tumors do not grow through the activity of cancer cells alone. Cancer-associated fibroblasts (CAFs) and various immune cells gather around cancer cells, forming a complex community known as the tumor microenvironment. These cells communicate by exchanging extracellular vesicles (EVs), tiny packages that carry biological signals between cells.

Through this communication, cancer cells become more aggressive, while surrounding cells help them spread to other organs and resist anticancer treatments. Conventional cancer therapies have primarily focused on directly attacking cancer cells, making it difficult to completely break this vicious cycle of support from surrounding cells.

Targeting both sides of tumor communication

To address this challenge, the research team focused on epidermal growth factor receptor (EGFR), a cell-surface receptor expressed on cancer cells and upregulated in activated CAFs.

By targeting EGFR, the researchers developed a degrader-antibody conjugate (DAC) that combines an antibody capable of precisely targeting these cells with a drug that selectively degrades cyclooxygenase-2 (COX-2) inside the cells. Once this precision-targeted agent enters the two cell types, it suppresses the production and secretion of extracellular vesicles that carry signals between them.

As a result, the communication network through which cancer cells and surrounding stromal cells reinforce one another is disrupted. In cell-based experiments, the treatment reduced CAF activation, cancer cell migration and tumor-promoting macrophage polarization. In an animal tumor model, it markedly suppressed tumor growth and remodeled the tumor microenvironment toward a more antitumor state.

Disrupting the broader tumor ecosystem

The study moves beyond conventional approaches that focus only on directly attacking cancer cells. By combining precision antibody targeting with targeted protein degradation, the new platform provides a strategy for disrupting the broader cellular ecosystem that supports tumor growth.

Yang of the Department of Integrative Biotechnology said, "Cancer cells constantly communicate with surrounding cells to create an environment favorable to their own survival and growth.

"This study presents a new precision anticancer strategy that simultaneously targets cancer cells and their supporting cells while disrupting the harmful communication network between them, thereby affecting the tumor tissue as a whole."

Publication details

Eun Hye Kim et al, Receptor-Guided Targeted Protein Degradation Collapses Extracellular Vesicle-Driven Tumor-Stroma Crosstalk, Journal of the American Chemical Society (2026). DOI: 10.1021/jacs.6c11538

Journal information: Journal of the American Chemical Society

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Experimental cancer treatment disrupts cell communication to suppress tumor growth in animal tests (2026, October 7) retrieved 7 October 2026 from https://medicalxpress.com/news/2026-10-experimental-cancer-treatment-disrupts-cell.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com